Global Markets Direct’s, ‘Toxoplasmosis Pipeline Review, H1 2014′, provides an overview of the Toxoplasmosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Toxoplasmosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Toxoplasmosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Toxoplasmosis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Toxoplasmosis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Toxoplasmosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Toxoplasmosis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Toxoplasmosis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Toxoplasmosis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Toxoplasmosis Overview 5
Therapeutics Development 6
Pipeline Products for Toxoplasmosis - Overview 6
Pipeline Products for Toxoplasmosis - Comparative Analysis 7
Toxoplasmosis - Therapeutics under Development by Companies 8
Toxoplasmosis - Therapeutics under Investigation by Universities/Institutes 9
Toxoplasmosis - Pipeline Products Glance 10
Early Stage Products 10
Toxoplasmosis - Products under Development by Companies 11
Toxoplasmosis - Products under Investigation by Universities/Institutes 12
Toxoplasmosis - Companies Involved in Therapeutics Development 13
Snowdon Inc. 13
Toxoplasmosis - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Drug Profiles 18
SND-226 - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
DNA Vaccine For Toxoplasmosis - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ROP-5 Vaccine - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
SNT-18 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Human Monoclonal Antibodies - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Toxoplasmosis - Dormant Projects 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables

Number of Products under Development for Toxoplasmosis, H1 2014 6
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2014 7
Number of Products under Development by Companies, H1 2014 8
Number of Products under Investigation by Universities/Institutes, H1 2014 9
Comparative Analysis by Early Stage Development, H1 2014 10
Products under Development by Companies, H1 2014 11
Products under Investigation by Universities/Institutes, H1 2014 12
Toxoplasmosis - Pipeline by Snowdon Inc., H1 2014 13
Assessment by Monotherapy Products, H1 2014 14
Number of Products by Stage and Route of Administration, H1 2014 15
Number of Products by Stage and Molecule Type, H1 2014 17
Toxoplasmosis - Dormant Projects, H1 2014 23

List of Figures

Number of Products under Development for Toxoplasmosis, H1 2014 6
Number of Products under Development for Toxoplasmosis - Comparative Analysis, H1 2014 7
Number of Products under Investigation by Universities/Institutes, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 10
Assessment by Monotherapy Products, H1 2014 14
Number of Products by Top 10 Molecule Type, H1 2014 16
Number of Products by Stage and Top 10 Molecule Type, H1 2014 17